Pharmaceuticals, Biotechnology and Life Sciences
Melanie Quan Advances to Philadelphia to Compete Against Top Students from Across the Nation, Canada and Germany SAN FRANCISCO–(BUSINESS WIRE)–lt;a…
MORRISVILLE, N.C.–(BUSINESS WIRE)–Worldwide Clinical Trials, Inc., (Worldwide) an award-winning, full-service, midsize, global CRO, announced today that Philippa Marshall, MD, BSc,…
Commits to improving the clinical care process for all stakeholders MEMPHIS, Tenn.–(BUSINESS WIRE)–TransMed Systems, Inc., a leading provider of technology,…
ALACHUA, Fla.–(BUSINESS WIRE)–Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that the Department of Defense…
DUBLIN–(BUSINESS WIRE)–The “Japan Generic Drug Market: Industry Trends, Share, Size, Growth, Opportunity and Forecast 2019-2024” report has been added to…
TRPC5 Inhibition with GFB-887 Protects Against Podocyte Injury and Proteinuria Associated with Focal Segmental Glomerulosclerosis and Treatment-resistant Minimal Change Disease…
HONG KONG–(BUSINESS WIRE)–Aptorum Group Ltd. (NASDAQ: APM), a preclinical stage pharmaceutical company developing and commercializing a broad portfolio of projects…
The publication of the 2018 Annual Report marks the public debut ofNovocure’s newly defined vision, mission and values. Novocure launchedits vision, mission and values internally to its nearly 600 employees atthe end of 2018.
The primary endpoint is the percent reduction in urinary oxalate frombaseline to six months. The Company expects to report initialILLUMINATE-B results in mid-2020.
standalone implantation of two iStent®Trabecular Micro-Bypass Stents in newly diagnosed primary open-angleglaucoma (POAG) eyes achieved a 35.3% reduction in meanintraocular pressure (IOP) to 16.5 mmHg after five years of follow-up.